Pembrolizumab Plus Trastuzumab and Chemotherapy for HER2-Positive Gastric or Gastro-oesophageal Junction Adenocarcinoma. Mol. Med. Com. [Internet]. 2023 Dec. 29 [cited 2026 Apr. 3];3(02):89-92. Available from: https://rootspress.org/journals/MMC/article/view/461